Showing posts with label alberta blue cross. Show all posts
Showing posts with label alberta blue cross. Show all posts

Monday, October 25, 2010

WSIB and the contracted or independent worker (Ontario)

Let’s talk about your issues as a self employed contractor, shall we?

If you are an “employee” your company must by law insure you for workplace related injury. This might explain why so many companies are forcing employees to go on contract, and hiring them back at higher wages in lieu of benefits.

And, this is not necessarily a bad thing for you as the contracted employee. There are tax advantages, and if done right, more protection options in areas of disability coverage that will put you in the driver’s seat. Nortel has proven that group LTD is not the be all and end all, and it should send shock waves through the corporate employees to realize they had better take measure to protect themselves. But we are here to focus now on WSIB.

Perhaps your client is looking to cut back on cost, and by hiring companies and contractors, they can avoid the high premiums of WSIB.

Specifically, what are your issues and shortfalls with the wsib-logoWSIB insurance program?

The best little graph I have seen so far is this one that compares the WSIB situation with that offered by private disability:

Workplace Safety & Insurance Board On the Job Coverage Only (Work Related Injury plus Illness)24 Hour Coverage Injury optional illness coverage at Home, Work or Play. Covers any type of injury or illnessExtended Health (Work Related Only)Extended Health (Blanket Coverage). Alternative to WSIB contracts may offer $10,000 to $100,000 of Accidental Medical Emergency coverage. Group or Individual Extended Health contracts offer blanklet coverage any type of medical coverage to the terms of the contract purchased.Rehabilitation discretion of WSIBReturn to work with Modified Duties*Unlimited Rehabilitation Benefit in good contracts, others limited to the limit within the terms of the contract. *Return to work once client is able to return to work in his own occupation thereafter any occupationWSIB doctor assessment of injury60 day coverage, options for higher sprain & strain coverage or no limit on sprain or strain Non Cancellable contracts with a 30 day wait offer NO limitation on Sprains & StrainsCoverage capped to reflect average industry wage1st year capped at $22, 567.00. Normal Rate for Owner Operator $5.78 per $100 of replacement Income based on net $32,000 of replacement income. Annual Premium $1,849.60Overall Maximum Combined of $6,000 monthly for both Loss of Income and Business Overhead Expense Reimbursement.Coverage based on Gross or Net Taxable Income. Average Rate for Injury Only Coverage $3.76 per day. Annual Premium of $1,349.88 or $112.49/mo. Add Extended Health Coverage Optional. Annual Premium $2,098.68.Long Term Disability to Age 65 or 70 based on any occupation, education, training and skill.Accidental Death & Dismemberment $300,000Accidental Death & Dismemberment up to $500,000Specific to Small Business Owners needsMandatory for Employees, Optional for Business OwnersInflexible to alternate coverage in place.Flexible. Purchase coverage by assessing your overall needs.

 I would add that the best policies will not force you to find a job outside of your occupation. And, this is important as your earnings increase with talent and experience. Why should you flip burgers at $7 per hour, when you have been trained at a specialty for $50 per hour? Why should you be penalized? Short answer – you shouldn’t!

It would seem there is a whole industry surrounding WSIB, it’s pitfalls, the complications of getting it, etc.

I just spoke to a client in his 30’s that was told by WSIB, that should he qualify, the premium would be 8.7% of his wage.

So, if he earned $3000 per month, the premium would be $261 per month.

Wow!

What would he be getting for that $261?

Well, what he is getting may better be described by what he is not getting.

If he was in a car accident outside of work and became disabled – nothing.If he got an illness such as cancer or a heart attack that rendered him disabled – nothing.any other accident outside of work time and duties – nothing again.

The point is, if you are going to insure yourself adequately, why not be in control and be insured for any reason that might cause a disability?

Are you any less in need of money for disability issues not covered by WSIB? No.

As brokers, we are able to access the best disability plans, at the best cost, and these plans are yours.

In other words, good disability policies will be portable, will not be cancellable, and the rates are locked in at the time you take out the coverage.

Some plans can and do pay back a portion of premiums if you cash in, at 25% or 50%, and some allow you to convert them to other forms of income streams at retirement – specifically long term care coverage.

This literally leaves WSIB and it’s offering in the “dust”.

Like all protection, for the money, what is the best value?

Well, it certainly is not the schedule of benefits offered by WSIB.

The company you are contracted with, and that requires you by law to insure yourself, needs to know you are covered. By getting good coverage, they can be given a copy and their liability is over.

WSIB reminds me of an option in life insurance known as AD & D (accidental death and dismemberment).

AD&D will double the amount of insurance if death is caused by accident. So, I suppose if you get diagnosed with cancer, it would be a good idea to drive off the nearest tall bridge to ensure your family gets enough money.

Crazy or what?

Give us a call, and we can take care of your needs properly. 1.866.856.6799

Post to Twitter Tweet This Post

Related posts:

WSIB alternatives in Ontario Houston, we have a problem!   And the problem for...Benefit plans ABC, 123 – Sesame Street style (Ontario & Alberta, Canada 1.866.856.6799) Why does insurance advice have to be technical and complicated?...What would you think of me if……? Let me ask you a question or two. What if...Insurance for Dummies 101: Are your insurance plans draining or ensuring cash flow? It was hard to put this topic out there. What...In Ontario and Alberta, Canada……………Call 1-866-856-6799  Make the call!    Wondering if benefit plans are really worth...

Related posts brought to you by Yet Another Related Posts Plugin.


View the original article here

Sunday, October 24, 2010

PHARMA: Reprieve for Amgen looking doubtful

In a story titled somewhat cryptically Medicare chief stands by anemia move (do they mean he’s trying to become anemic?) Reuters reports that CMS is not backing down from its decision to radically cut payments for anti-anemia drugs for chemotherapy patients. In English this means that Amgen’s Arenesp (& Epogen, though that’s not officially for cancer patients) and J&J’s Procit (which is Epogen re-marketed by J&J) are not going to recover their lost sales from last year.  Those sales began to be lost when studies revealed that the fairly rampant use of those drugs was overuse, and also that they were causing some severe side-effects.

Of course for reasons that we all know (e.g. they have little to do with clinical endpoints and more to do with financial ones), community oncologists have flipped out. I do like the response from Dr. Barry Straube, the chief medical officer at CMS. He said:

Of course the real impact of this was not on patients per se, but on Amgen’s stock price, which has not had the best of years. The little rally late last year was on hopes that CMS would change its mind. I’m afraid that that gravy train looks like it’s over.

What do we do about the anemia drug controversy?

Most doctors and patients would agree the drugs are very helpful for patients when used to correct "severe" anemia, which can be debilitating and even life-threatening. The drugs reduce the need for somewhat risky blood transfusions and can give patients more energy and improve their quality of life.

''These are drugs that were presumed to be entirely safe, given for supportive care and to improve quality of life,'' not to actually treat cancer, said Dr. Eric Winer, director of breast oncology center at the Dana-Farber Cancer Institute in Boston. ''So any concern that they could shorten someone's life are taken quite seriously.''

There is little evidence that the drugs make much difference for patients with "moderate" anemia. Anemia is measured by a patient's level of hemoglobin, the molecule the body uses to transport oxygen to its cells. Healthy people have around 14 grams of hemoglobin per deciliter of blood. Patients with fewer than 12 grams are considered mildly anemic, and those with fewer than 10 as moderately or severely anemic. The labels on the drugs approved by the FDA encourage doctors to aim for a hemoglobin level of 10 to 12.

Critics of the drugs say their increased use has been driven by profit. According to Dr. John Glaspy, director of UCLA's Outpatient Oncology Clinic, one complicating factor is that oncologists make significant revenue buying cancer drugs from manufacturers and charging patients a higher price for receiving the drugs in their offices. That profit motive could influence some doctors' decisions.

Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, told UPI last year that "probably more than a billion dollars is spent on erythropoietin each year, which makes it one of the most expensive cancer drugs." A six-month course of treatment can cost more than $10,000 per patient.

After this issue had started to be reported, U.S. Oncology took an 8-10 million dollar hit in its first-quarter SEC report last year, including reduced pre-tax income due to lower use of anemia drugs. They also were handicapped by CMS stopping the Medicare Demonstration Project which paid chemotherapy providers $130 per report, per infusional-chemotherapy recipient, on a patient's level of nausea, vomiting, pain and fatigue, something that Congress found out that they were supplying free of charge anyway.

A continuance of the Medicare Demonstration Project would have exacerbated existing economic and clinical problems instead of resolving them by increasing the temptations for physicians to overuse injectable drugs and promise to aggravate the economic problems Congress attempted to fix with the new Medicare law.

A New York Times article reported last year that Federal laws bar drug companies from paying doctors to prescribe medicines that are given in pill form and purchased by patients from pharmacies. However, companies can rebate part of the price that doctors pay for drugs, like the anemia medicines, which they dispense in their offices as part of treatment. Doctors receive the rebates after they buy the drugs from the companies, but they also receive reimbursement from Medicare or private insurers for the drugs, often at a markup over the doctors' purchase price.

Although the new Medicare bill tried to curtail this kind of drug concession, private insurers still go along with it. What needs to be done is to remove the profit incentive from the choice of drug treatments. Let's take physicians out of the retail pharmacy business and force them be doctors again!

Posted by: Gregory D. Pawelski | Feb 9, 2008 6:17:12 AM


View the original article here

Saturday, October 23, 2010

The other Michael Jackson mega-mix

By Matthew Holt

Never ones to be shy with an interesting view into celebrity pharmacology (and truth be told responding to a little tickle from me) the inventive folks at PharmaSurveyor have added Michael Jackson to their celebrity drug cocktail page.

It’s an interesting way to show the dangers of multiple drug regimens, and a great way to show off PharmaSurveyor’s computational capabilities of analyzing multiple drug regimens at once. (PharmaSurveyor calls those assessments surveys). You can find it on http://www.michaeljacksondrugs.net/ which has a static picture of Michael Jackson's survey and links to the interactive one on PharmaSURVEYOR.com. (FD I’m an advisor to PharmaSurveyor with a few stock options)

July 6, 2009 in Health 2.0, Pharma, pharmaceuticals, Technology, Web/Tech | Permalink

We've also covered Jackson's medical conditions as well as those of other celebrities. Please have a look.

Posted by: DrB | Jul 7, 2009 7:15:01 AM


View the original article here

Viagra prescribed more safely online than in regular practice?

They looked at records of questionnaires taken and prescribing decisions made by a licensed, regulated online pharmacy called KwikMed — that is trying very hard to establish itself as ethically and legally different from those fly by night guys whose spam comments will rapidly attach to this post! They looked at the various outcomes and end points including safety and level of counseling and found that the online system produced results as good as or better as those found from a big records review in an unnamed (not surprisingly!) large multi-specialty clinic in Salt Lake City, UT.

Now obviously the ability to create an online questionnaire for specific conditions with clear inclusion/exclusion criteria (like ED or hair loss) means that as clear a picture can be gained in most cases from a good history taken online--and probably the history will be given more honestly by the patient. Plus the rigor of the history is probably better than one taken in a rushed office visit. And then it gets reviewed by a doctor who may recommend another approach but most times agrees and sends the Rx on to be filled.

I met with the Kwikmed folks randomly last week (and yes they were excited about the article). They've got a pretty sizable business in terms of ED drugs and hair loss drugs and are keeping quite a few doctors busy. The next question is can this type of study justify more online prescribing in different drug categories, or of course can they extend online visits into other categories, such as allowing people to order their own lab tests.

They of course think the answer is both. 

Of course, the core savings that Kwikmed delivers is that you don't have to pay for the doctor visit and the prescription, as they bundle it together. When it's a cash visit and a cash prescription as many of those lifestyle drugs are, then it makes sense for the patient. Of course the same is true for those paying in a high-deductible scenario.

But the more general point is that it'a another piece of evidence that at least some medical care can effectively go online at a lower price point than traditional care.

And why not? The world's flat, right?

Why shouldn't every benefit, including pricing leverage, wholesale access to provider or supplier services, and user friendly quality "indicia", be accessible to those in need?

As mentioned elsewhere on THCB in the "The Affordability Factor" [which has been met by silence from the author], why not extend the value of group purchasing to the general public and specifically those not represented by third party "aggregators", e.g., health plan, insurance company, TPA, MSO, MCO, PSN, PHO, OWA, etc? Why does one have to be enrolled in a diminishing benefits health plan or variant thereon in order to benefit from market pricing via purchasing entities?

Why are private plans, and the government the sole beneficiaries of paying $.15 to $.30 on the dollar while the uninsured must operate in the world of retail medicine?

If the web can facilitate legitimate pharmaceutical access, and perhaps encourage a greater level of diagnostic honesty then so be it.

Posted by: Gregg Masters | Aug 8, 2008 12:25:17 PM

Cardio Cocktail have seen great resutls too. Check out www.thecardioshop.com to find out more.

Posted by: Nicole | Aug 10, 2008 5:41:46 PM

very interesting and informative post. for more information on viagra check out http://kwikmed.com/prodinfo.asp?p=viagra

Posted by: viagra | Aug 22, 2008 11:28:41 AM

very interesting and informative post. for more information on viagra check out http://kwikmed.com/prodinfo.asp?p=viagra

Posted by: viagra | Aug 22, 2008 11:28:53 AM

I think Viagra is a real important product in these days!
And the fact,that you can order it without any prescription
its just perfect.

Posted by: Viagra | Sep 30, 2008 5:20:24 AM

check this blog with alot answers about viagra and other pills

Posted by: andrew | Dec 8, 2008 5:23:05 AM

sorry didnt place url: http://whydoineedviagra.com/

Posted by: andrew | Dec 8, 2008 5:24:45 AM

nice info about viagra thanks

Posted by: viagra | Nov 8, 2009 5:06:49 AM

The best pill in the world, to me they very much helped.If you notice any changes in your vision while taking this drug, call your doctor or health care professional as soon as possible.

Call your health care provider right away if you have any change in vision.

Contact you doctor or health care professional right away if the erection lasts longer than 4 hours or if it becomes painful. This may be a sign of a serious problem and must be treated right away to prevent permanent damage

Posted by: Rick | Dec 6, 2009 2:39:05 AM


View the original article here

POLICY/PHARMA: DEA's insane persecution of pain patients continues

Just in case you needed to be reminded that the DEA is a refuge of evil scumbags and needs to be abolished, here's another exhibit (from the good people at DRCNet):

Federal agents arrested Dr. Stephen Schneider, operator of the Schneider Medical Clinic, and his wife and business manager, Linda, on a 34-count indictment charging them with operating a "pill mill" at their clinic. The indictment charges that Schneider and his assistants "unlawfully" wrote prescriptions for narcotic pain relievers, that at least 56 of Schneiders' patients died of drug overdoses between 2002 and 2007, and that Schneider and his assistants prescribed pain relievers "outside the course of usual medical practice and not for legitimate medical purpose."

Darren Baker is another patient who swears by Dr. Schneider. The operator of a tree gardening service, Baker has bone spurs in his knees from years of climbing, and two years ago, he fell out of a tree, shattering both his heels. "They put all kinds of hardware in my heels, and I have to have pain medications just to walk," he said. "With the pain meds, I can't walk real well, but without them, I can't walk, period. Dr. Schneider was the only one who would treat me."

Now, like Sauers, Baker is in search of a doctor. "I haven't found one yet," he said. "I got a list today, but most of them are turning you away if you're associated with Dr. Schneider. If I can't get another doctor, I won't have any option except to retire and go on disability. I take my medicine to be a productive member of society," he said angrily. "I need my meds to survive and pay my bills and fight the daily grind. This really goes against our constitutional rights. How the hell can I pursue happiness lying in bed?"

The DEA has repeatedly lied about its own opiate prescribing guidelines and has gone after soft “targets” like doctors—from whom it can easily steal assets—not to mention people legally dispensing marijuana in states where its legal. And don’t talk to me about “the law”. All Democratic candidates say they’ll stop the DeA raiding med marijuana clinics. Are they advocating that the DEA breaks the law? Perhaps the DEA should arrest them.

Clearly the DEA couldn’t give two shits about the lives of the patients for whom opiates is the effective solution. This organization is beyond salvage and needs to be abolished. Its administrative duties can be absorbed into the (hopefully newly funded and reformed) FDA.

Just one more piece of work awaiting the next rational occupant of the White House…..if we get one.

I agree that the DEA must be restrained in these matters. However, every pharmacist (and I'm a pharmacist) in a particular area can tell you exactly which doctors are are legitimately managing pain, which are completely naive about dishonest patients, and which are running pill mills. Just ask 5 of your local pharmaicsts, and I guarantee you'll discover which are the truly bad eggs.

Posted by: adam | Feb 7, 2008 4:51:05 PM

We do not know enough facts. The DEA does not usually go after people who merely cut corners. They may just call to discuss practices. They usually prosecute docs after people have died of overdoses, in this case 56. I would like to hear more facts or to read the charges. The licensing board also tried to suspend the license, so it is not solely the DEA complaining.

Posted by: Supremacy Claus | Mar 3, 2008 5:11:49 AM

The DEA is an out of control agency. Because of these evil scumbags legitimate pain patients cannot get adequate doses of medication necessary to manage their pain. This agency serves no legitimate purpose and seems to be a repository for sociopaths. A quick google search will reveal millions of websites and posts documenting their corruption and propensity for violence against non violent offenders not to mention stealing assets from innocent victims of this evil agency.

Posted by: j davis | Mar 13, 2008 9:24:02 AM

The DEA is an out of control agency. Because of these evil scumbags legitimate pain patients cannot get adequate doses of medication necessary to manage their pain. This agency serves no legitimate purpose and seems to be a repository for sociopaths. A quick google search will reveal millions of websites and posts documenting their corruption and propensity for violence against non violent offenders not to mention stealing assets from innocent victims of this evil agency.

Posted by: j davis | Mar 13, 2008 9:24:27 AM


View the original article here

Flacks peddle false "reality"

Such a pity that the NY Times has been so beaten up by the commies amongst us that it actually now feels that it has to point out where Peter Pitts and Janet Trautwein get their money. Although, as per the last time it let Pitts write an op-ed, it didn’t mention his day job as a PR man for pharmaceutical companies. After all, who could be opposed to “Medicine in the Public Interest” — after all it is in the interest of the public to pay for all and any medicine at any price that PhRMA chooses, right?

And let’s not get started on underwriters (for whom Trautwein is the main flack). After all Grace-Marie Turner thinks that they’re the health care heroes! Perhaps they’re heroes because they drive sick people into the uninsured population so that the under-paid clinical staff working in America’s public and community health system get to show their worth by caring for them —even if they’re less heroic than underwriters.

But that’s OK, Pitts & Trautwein can be printed in the NY Times cherry-picking problems with other countries health care systems. Because as we all know there’s absolutely nothing wrong with ours, eh?

And why should Pitts quote the peer-reviewed 2007 Commonwealth Fund study that showed that waiting times for surgery were longer in the US than in the communist hell-hole of Germany, when instead he was able to cite an 11 year old study about longer waiting lists for one specific type of surgery in the Netherlands, which has completely revamped its health care system since then. Something he and Trautwein have helped stop us doing — preserving a dismal status quo they obviously want to maintain.

Those two wouldn’t last 92 seconds in a debate with Uwe Reinhardt or Hillary Clinton.

On the other hand, there’s no letter from Karen Ignagni to make up the trifecta. Did she negotiate some summer vacation time along with her $1.3m salary?

WEIRD

The Times has many faults (too much B.S. about alleged "single-payer") -- but this is NOT one of them. Anyone dumb enough to believe that a Ralph Nader fan wrote that after this tagline --

"The writer is president of the Center for Medicine in the Public Interest, a nonprofit organization that receives financing from pharmaceutical and biotech companies."

deserves to live in the U.K., France or Canada.

This was just freakin' weird.

Posted by: Russell | Aug 15, 2008 11:18:02 AM

Russell--

No, it wasn't weird.

It's part of a pattern at the NYT (where I have worked.)
The lack of discosure on where op-ed writers are coming from is disgraceful.

Posted by: Maggie Mahar | Aug 15, 2008 8:34:18 PM

Madam, with a 1000 respects -- what the heck are you talking about?

Any normal American who has actually worked a real job (e.g., McDonald's) knows when she/he is being spun. As in, when the boss asks for a volunteer -- don't volunteer until the details are known.

Someone who gets $$$ from the pharms is NOT going to oppose the pharms. This is Comm 101, madam.

My God -- I cannot believe valuable electrons are being wasted in stating the plainly obvious. What is next -- there are no illegal immigrants in the USA?

Weird. Just frackin' weird.

Posted by: Russell | Aug 16, 2008 10:32:09 AM


View the original article here

Friday, October 22, 2010

TECH: Drugs & technology--Allscripts and SafeMed

They also have a very cool video called Paper Free health care (I spot some inspiration from the Health 2.0 video!)

I also got the chance to meet a much smaller company called SafeMed. Rich Nossfinger & Ahmed Ghouri hasve built a very very sophisticated rules and processing engine which can interpret drug data and embed that decision support into patient specific indications. Very intriguing stuff and you can learn more by listening to this interview (although they weren't allowed to let me tell the world in advance that they are one of the first partners in the Google ecosystem. Here's the SafeMed interview.


View the original article here

PHARMA: Stunt doubles in pharma DTC?

I’m sure (well I’m not sure but I’ll cheerfully and casually postulate) to keep you all amused on a Friday) that there are many possible overlooked problems with Lipitor and the statins. I’ve heard of severe muscle pain, even amnesia. But then again most cardiologists and the medical establishment recommend statins very widely and the general medical opinion is that they’re under-used.

I’m reading an interesting book The Last Well Person by Nortin Hadler whom I had the pleasure of meeting at the FIDMD meeting a few weeks back. Nortin is not exactly modest(!) but he’s very amusing and has firm firm opinions. In the book he systematically goes through the randomized clinical trial evidence of the value of much heart treatment including angioplasty, heart bypass, and statins. And his analysis from the West of Scotland trial (which admittedly was using Pravachol not Lipitor) is that statin use made only marginal absolute improvements in heart attacks and essentially no difference in overall mortality.

But is Congress investigating whether the medical establishment has been lead astray or is leading us astray? No.

Apparently the most important question is whether Robert Jarvik actually rowed his own boat in a Lipitor commercial….

February 8, 2008 in Pharma | Permalink

Congress really has its priorities straight. Did Jarvik row his own boat? Did Belechik steal signals from the Jets? COME ON, GUYS! Let's get to the really tough questions: Does Shaq use Nair to keep his dome shiny? Does J. Lo get collagen injections in her butt? Is Lou Dobbs really a genetically modified woodchuck? (Tape at 11.)

Rome burns . . .

Posted by: tcoyote | Feb 9, 2008 4:20:02 AM


View the original article here

Big pharma has big problems

Big pharma has big problems. The root cause is a lack of research and development productivity, which means a dearth of new products to make up for looming patent expirations. Something near half of big pharma’s revenues will be threatened by generic competition within the next three to four years, and that will radically change the face of the industry.

The R&D productivity problem isn’t exactly new. When I was at the Boston Consulting Group (BCG) in the mid-90s we were already talking about the “NCE gap,” which referred to the number of new chemical entities that needed to be developed to justify pharma companies’ valuations at the time. Back then, there was still a possibility that new discovery tools would boost productivity and prevent a collapse of the industry.

Over the next decade or so, pharma largely managed to maintain its revenue growth and valuations, but things weren’t as healthy as they looked. The revenue growth was due to price increases, new indications for existing products, changes to guidelines (e.g., blood pressure, cholesterol) that increased the number of people who were recommended for drug therapy, combination products, new formulations, growth outside the U.S., and the arrival of the Medicare Part D prescription drug coverage. Almost all of these growth levers are now tapped out.

According to the Washington Times (Drugmaker ads to target Obama idea) the pharmaceutical industry is now planning a large advertising effort to undermine President-Elect Barack Obama’s plan to have the government negotiate drug prices on behalf of Medicare, rather than leaving it up to the PBMs that do the job now.

My old BCG buddies are at it with a new report, which the Times cites.

Giving Medicare the authority to negotiate drug prices - a provision that they currently don’t have - would cause the pharmaceutical industry to lose $10 billion to $30 billion in annual revenues, according to a report released last month by the Boston Consulting Group.

“If you start to take a pretty big price decrease out of that large market, it has an enormous impact on drug companies and really their ability to generate their type of shareholder return that they have had in the past,” said Peter Lawyer, a senior partner with Boston Consulting.

According to the Times, the ads will “tout the importance of free-market health care” and may try to have the same impact as the famous Harry and Louise ads of 1993 that undermined the planned Hillary Clinton-led reform bill. (By the way the brains behind the Hillary effort was ex-BCGer Ira Magaziner.)

If that’s really the aim, someone is misjudging the mood of the public. People aren’t looking for “free-market” anything at the moment, especially when what the pharmaceutical industry really means by “free market” is pricing freedom for themselves. And remember, drugs are protected by patents, which are granted by the government, not the free market.

Here’s some friendly advice to the pharmaceutical industry: don’t make the mistake of attacking the policies of our new President. Such a move is likely to backfire.

David E. Williams is co-founder of MedPharma Partners LLC, strategy consultant in technology enabled health care services, pharma,  biotech, and medical devices. Formerly with BCG and LEK.

When I see patients in my (nonsurgical specialty) practice, elderly patients (and often younger ones with high medical usage) with long lists of medications, I feel that we are really diverting a lot of wealth for little in return. For most costly drugs, there are reasonable generic substitutes (of course not for all drugs and for every patient, I am aware of allergies, side effects, interactions). And when I see elderly people who get a lot paid by medicare part D and still have substantial copays, I do think that for these folks, there basically is a second tax, and a very high one.

Posted by: rbar | Nov 19, 2008 9:04:19 AM

Pharma is just tyring to fend off challenges to their revenues and their profits but the hand-writing is on the wall. Economist had a brief piece on it but the future of pharma companies profits is going to be in the BRIC countries and non-G20 countries outside of North America and the EU zone.

http://www.economist.com/business/displaystory.cfm?story_id=12601852

Posted by: MG | Nov 19, 2008 9:53:04 AM

When the new, expanded Medicare for All is implemented upon the passage of H.R. 676, the pharmaceutical companies will then have to begin negotiating their prices with the government as they currently do with the VA. This will bring drug costs in the USA more in line with those much lower costs that are found in most every other country around the world.

If you believe that affordable health care in America should be a right and not a privilege, then join HR676.org today and your voice will be heard.

Larry Pius, Dir
www.HR676.org

Posted by: Larry Pius | Nov 19, 2008 10:37:08 PM


View the original article here

Thursday, October 21, 2010

What does the upcoming EI inclusion for the self-employed mean?

The unemployment insurance opportunity will be extended to allow short-term disability to be addressed for the self-employed. Weighing the need and importance to the client should be compared with the cost, as with all insurance opportunities.

In 2010, the Government foresees the inclusion of the self-employed to the employment insurance system in a limited way.

How limited?

Well, actually limited to what makes sense.

As a self-employed person you will not be able to claim for job loss (because you are your own boss), but you will be able to claim for disability, maternity leave, and other medical reasons.

In short, this means that the issue of short-term disability can be addressed, and the analysis should form part of your overall insurance planning.

The system will be voluntary, so an insurance broker should weigh in the importance you as a client would put on short-term disability.

Premiums can range up to $60 per month approximately, depending on income.

Post to Twitter Tweet This Post

Related posts:

What can Nortel teach us of the pitfalls of group long term disability plans? One of the best arguments for personal, individual disability plans...

Related posts brought to you by Yet Another Related Posts Plugin.


View the original article here

Heard of Cancer? Heard of DCA?

Here is an eye-opening and thought provoking video of an Alberta labs findings that has promise. Here is the link to information on their website. Note this video was from 2007:

Post to Twitter Tweet This Post

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.


View the original article here

Wednesday, October 20, 2010

Donald Light sticks it to PhRMA and Tauzin, again

By Matthew Holt

Over the years PhRMA must be getting pretty sick of Univ of Medicine and Denistry of New Jersey Professor Donald Light. He’s made a cottage industry of pissing on the commonly-trumpeted propaganda that only American drug research is effective, and that high prices for drugs in the US cross-subsidize lower prices elsewhere in the world. And in Health Affairs this week he does it again. Essentially Light shows that the added R&D spent in the US compared to Europe doesn’t give much bang for the buck, and that not many breakthrough drugs have been created anyway—something that PhRMA knows all to well as it looks at its shrinking pipelines.

CODA: Read Michael Cannon’s amusing take on PhRMA’s Billy Tauzin’s performance here.

Matthew,
Count me on the same. I have been saying the same things for a long time. Pharma has pretty inefficient process, and have huge amount of waste. If you look into, their innovation line is broken. the only way they seem to do anything is by acquisition and that is where their innovation is comming from. The best way I describe the inefficiency of their process is this: " We have spend trillion over the years on cancer research and in return all we got was viagra".

They need to improve their R&D process and even more the innovation process. Problem is they are too busy thinking that they are the best till you point to their performance.

rgds
ravi
blogs.biproinc.com/healthcare
www.biproinc.com

Posted by: Dr. Pandey | Aug 26, 2009 6:50:00 AM

A couple of years ago I heard or read -- and now can't remember or rediscover where -- that not a single one of the small-molecule drugs in the portfolio of Pfizer, the largest drug company in the world, had been created by a Pfizer scientist. They had all been created either overseas and the rights purchased; by a research university scientist and the rights purchased; or by another company Pfizer later acquired.

If I can confirm this to be true, it's pretty amazing. Can anyone else confirm or deny?

Posted by: Rick | Aug 26, 2009 12:58:29 PM

My close family members have been prescribed drugs for bloood pressure, diabetes, and other ailments. I am not happy with this.It is my observatation that many drugs seem simply to move a sympton, or condition of not healthy, to another area or function of the body.

Posted by: john | Aug 20, 2010 6:42:20 AM

The relentless search for a drug to cure anything and everything I am sure has great value. The body of science about the internal chemistry of the human body, and of the animal and plants words, I am sure is of immense value and is meant to be.

However as regards people being allowed their health, why does no one take a look at, how miserable people actually feel, and how they are often critical of themselves, and critical of their lives or their world, and ask has this got something to with their health?people are?

Also, very importantlym, why does no one look at how many people of the world, seem to find their understanding of it, is complete, when they blame America and the West for everything,everything that goes wrong, everything in their view that ever has gone wrong, without ever being challenged?

Does this childish approach to their own lives and their outlook upon their world, by means of it's continuous and never ending nature, have an impact upon the health of the world's citizens? Blame, blame, blame,on and on?

Are we letting this take away our energy and our health by always, it seems, giving in, and even encouraging this view point?

Posted by: john | Aug 20, 2010 6:58:36 AM

None of the links work, and the Health Affairs website does not list any publications by Donald Light in 2010. What's up?

Posted by: Meryl Nass | Aug 30, 2010 6:25:02 AM


View the original article here

My forecast: a sad conclusion to the health care bubble...

Brian Klepper and David Kibbe have written a terrific piece on how and why health care is in a handbasket and wondering where it’s going. But as we ex-futurists know, there’s lots of luck required to make a good forecast.

When I met Brian five years ago he told me that the sky would fall within five years, and at the time he was trying to persuade players in the health care system to self-reform. He suggested to them that the alternative would be soon be much worse.

I said, “no no, it'll take longer (10-15 years) and the system players will never self reform”. Instead I thought “reform” would be be done to them by the government when the system hit crisis. My guess was a combination of Medicare with 5 years of baby boomers on board and a middle class with 80 million uninsured would arrive around 2012–15. And then the brown stuff would be hitting the whirly object soon after that when the Chinese wanted their money back.

As it turns out we were both wrong and both right.

I was right to think that the system would never self-reform and that the players are still delusional about the long-term consequences, as they fight to maintain their short-term interests. The current activities of AHIP, PhRMA & ADVAMED are proving me right.

Brian was right to say that crisis was coming to health care in more like five rather than 15 years. But, Brian was lucky in his forecast because it's currently the wider economy taking health care down, not vice versa. But as health care becomes a bigger piece of a shrinking pie, the reverse is a real risk. If employers can barely afford to add $14,000 family coverage in good times, things sure as hell are not going to get better when employment is falling off a cliff at the rate of almost a million jobs being lost every month. And of course, even those on the government nickel are going to find that they’re not immune—especially as cities and government agencies find that they’re going to have to account for future liabilities and have balance sheets that look like GM’s.

So I think the worse things get on the economy and/or in the system, real reform remains inevitable--probably coming in the shape of de facto single payer  (other than for the 15% at the top) with price controls and fixed budgets. Which looks somewhat like the UK without the pay for performance part. But I still think it’s a few years off.

Sadly, we have probably one shot at doing this right before then--and by right I mean doing two things. #1 Creating a universal social insurance pool which has a dedicated tax base (or at least a politically visible cost). And #2 creating an Enthovian/Dutch system of rewarding private intermediaries to ensure providers reduce cost while improving both outcomes and the patient experience.And I increasingly think we're going to have to do those two things effectively at the same time. (I used to think that we could do #1 and #2 a little later).

But instead it seems that we're going to blow it mainly through Presidential and Senatorial timidity (not to mention health industry opposition). Instead, as I’ve been saying for a while, it seems very real that we’re going to leave the industry in charge of fiddling while Rome burns, and come up with some type of unenforceable pay-for-play withut real insurance reform--meaning we don’t do my #1, and leaving in place the current mess of FFS and peverse incentives meaning we don’t do #2.

And by the time we’ve seen in a few years that what we’re about to do won’t work, there’ll be no appetite for getting it structurally right.

If a social pool is created and funded through tax $$, do you agree that steps must be taken to ensure that individuals take more responsibility for their own health? If not, I think you run the risk of providing even more of a disincentive for citizens to take care of themselves than we have now.

Posted by: Deron S. | Mar 12, 2009 3:28:30 AM

Thanks Matt for the post.

Deron - What ideas do you have? It's difficult for financial incentives to fairly take into account random genetic variation, family history, how good your parents were at instilling healthy habits and raising you in a healthy lifestyle, the health of your mother while she was pregnant with you.... these things (especially the latter) have a greater impact on your health than any behaviors conducted while an adult.

Posted by: Read | Mar 12, 2009 4:11:53 AM

Everyone already has responsibility for his own health, Deron -- no one gets sick on purpose. People who live a so-called healthful lifestyle aren't any less likely to need health care than anyone else. No matter how carefully you live, you can still get hit by a bus, contract contagious diseases, fall heir to hereditary disorders or injure yourself while doing your exercises.

In fact, the people who "take care of themselves" may well cost the system the most: If they live longer, they'll need more services over time, not to mention costly care for the inevitable conditions of the aged.

Posted by: Ill and Uninsured in Illinois | Mar 12, 2009 4:24:43 AM

This post is a case study in why Matthew Holt is among the very best health analysts working anywhere today, and why his readership, leadership and influence have, by hard work and deep smarts, outstripped many in much more lofty and easily-won positions. Knowledge of a vast, complicated industry is rare, but insight is rarer.

I agree with everything Matthew has to say here. It is one thing to be able to intuit the vectors that are leading down a clearly defined path. It is quite another to accurately predict when the calamities will finally strike. But these are times we "ex-futurist(s)" - I like Matthew's use of that term - feel like Cassandra, Priam's daughter who could see but could not prevent the sacking of Troy.

And to extend that metaphor a little more, Matthew has also hit on what could be the Achilles heel of the current reform dynamic: Presidential timidity and a worrisome coziness with the industry leaders who have led us precisely into our current crisis.

Posted by: Brian Klepper | Mar 12, 2009 5:11:10 AM

Dear Matthew: I am not certain I agree with you, Matthew, either with respect to the analysis of the problem or its potential solution: because, in my opinion, things are already much more out of anyone's control than even we "ex-futurists" imagine.

There are two ever-present characteristics of market bubbles that I've experienced in my own lifetime, which seem also to apply to those I've read about from other periods. The first is that almost no one sees them coming. And, when a few people warn of the dangers of the gap between the inflated valuations and intrinsic values, and how this gap must inevitably close at some point, the warnings are routinely dismissed, the messengers scoffed at or worse. Second, after the collapse of the market (homes, stocks, dotcoms, tulips, health care services), virtually everyone says "we could have, should have, seen it coming."

I think we are dealing with powerful mechanisms of denial, greed, and shame that are built into all of our human systems where very large amounts of money are generated through market transactions and series of intermediaries, including those systems we have built for the payment and delivery of health care services.

So, Matthew's approaches #1 and #2 are eminently rational, and they might work well if the inherent psychology of market bubbles was itself rational. Which it is not. The longer the bubble persists, the more irrational we become...right up until the moment it bursts. I think, Matthew, you concede this point, when you invoke fantasy and the leadership of the health plan membership group in the same sentence!

I don't think the issue here is about who is right, and who is not right, about the timing. No one is keeping score that I know of. The only meaningful issue is how to avoid the pain and chaos that a sudden implosion of the health care economy might impose on all of us in the rest of society, the kind of pain and chaos that we've just seen with our banking system debacle.

The first step in that process seems to me to recognize the risks of continuing to deny how unbalanced and unstable our health care economy truly is. To come out of denial, wake up, stop thinking that it's all going to turn out fine after all. Brian and I are trying to be messengers of those signals that indicate the instability of inflated health care prices all along the complex supply chain involved, from insurance premiums to X-ray machines to EOBs for outpatient procedures that cost 10x what they should, or what they actually do cost, in other countries.

Thanks for your post, Matthew. This is a good conversation to be having. DCK

I think that President Obama "gets it." He's several times made the point publicly that the inflation of our health care costs is a structural flaw in our overall economy that inhibits growth and robs investment from sustainable new areas of development, e.g. renewable energy, education, and green sciences.

Posted by: David C. Kibbe, MD MBA | Mar 12, 2009 6:19:51 AM

David, I think you and Brian (and others like Alan Greene) are doing a terrific service warning others about the bubble potential in health care. And you've been doing that at least since the rumblings in the wider economy became visible.

But there's one more aspect about bubbles, which is that even if you think sytemically it's a bubble, you almost have to get sucked into it for your own good--at least in the short term, or you'll miss the $400 increase in Amazon stock that other fund managers got, you'll miss on the 100% appreciation in house prices, or whatever, and your short term position will not be as good as everyone elses. Clearly, we have a set of health care players who are still looking to get a short-term advantage (e.g. AHIP's desire for new members and new money while giving up not much), and who have little to no appreciation for the longer term consequences for their collective action.

So we essentially agree about the nature and degree of the bubble/crisis. Where we may disagree is how forceful Obama is likely to be to create the solutions to as you correctly say "avoid the pain and chaos that a sudden implosion of the health care economy might impose on all of us in the rest of society, the kind of pain and chaos that we've just seen with our banking system debacle."

The signs coming from the White House are better than we've seen in 28 years. But they're not enough to match the crisis if it's coming right now. I hope I'm wrong -- actually I hope we're both wrong. But I fear we're right.

Posted by: Matthew Holt | Mar 12, 2009 7:16:59 AM

My first reaction to Brian/David's post was similar to tcoyote's:

Sorry Bryan and David, the health system is not "going down the tubes". Not yet, anyway. It is strong enough and government subsidized enough that if it does, most of the rest of society will have collapsed ahead of it...

But then I thought further....

Compare the U.S. health care system to the rest of the world from an economic perspective. We spend close to double the average GDP on health care when compared to other developed countries, yet we get mediocre results in health outcomes and longevity.

How can you NOT define this as a "bubble"?

The value of this article is in its deliberate provocation -- forcing us to think differently.

Posted by: Vince Kuraitis | Mar 12, 2009 10:27:35 AM

Thank you for these insights, Matthew.

Much of what you says certainly seems true. I would add, though, that it looks like AHIP is going all-in for their bailout...which would be a mandate-first plan, with the guarantee that they can stay in business forever as a result.

This would be a politically-fascinating situation. Arnold Schwarzenegger's health plan fell apart mostly because of the mandate it included ("what's the fine?"). Nationally, I imagine a mandate would provoke the same furious opposition from the healthcare reform grassroots.

Posted by: Shum Preston, National Nurses Organizing Committee | Mar 12, 2009 2:08:15 PM

Well, Matthew, I'm sure we certainly agree about most things! My question is whether anything that President Obama says about health care reform would be determinative or not. I don't think he's capable of controlling the "downsizing" of health care in the short term, so I'm not as disappointed as you are that he's not articulating an alternative that would, somehow, avert a crisis.

What President Obama is doing very well is stirring the debate, in which we're taking part. He has set an expectation for significant change, and set all of the participants/stakeholders into motion. That is creating a new transparency, slowly but sure.y. We are all asking "who will benefit from this or that change?" And who will not benefit?

And this is within the first 2 months of his presidency!

DCK

Posted by: David C. Kibbe, MD MBA | Mar 12, 2009 3:31:18 PM

Read - I would suggest baseline health risk appraisals for everyone, possibly when they renew their drivers license. Then we could have periodic screenings to look for problems. I'm not suggesting we punish people that inherited health problems, but we are a sick nation and that is a significant cost driver that many of our discussions ignore. I would be interested in doing a "stress test" on the healthcare systems of the OEDC countries using a sick population like ours. It would be interesting what it does to their health costs as a % of GDP.

Ill and Uninsured - You made several comments that are worth further discussion. No one gets sick on purpose, but many are leading unhealthy lifestyles and making themselves sick. I'm not sure why that's acceptable.

Getting hit by a bus is highly unlikely. Obesity is becoming increasingly likely, even among young children. I don't know about you, but I think an obese 6 year old is a big red flag, as is a pregnant 14 year old. Those are things you'll find in this country in far greater numbers than any other country.

If people cost the system more because they are healthier and live longer, that sounds like a win for the healthcare system. The cost per year of productive life would be far less. They should, in theory, be able to work until a later age to contribute to society.

I'm intrigued by the "inevitable conditions of the aged". Can you give example of that? Conditions you say are inevitable might actually be preventable. I'm concerned that chronic illness has become so commom among the elderly, that we just accept it as inevitable.

There is a VERY important point that should be discussed. Just because we are healthy now, doesn't mean that unhealthy behaviors we are engaging in won't end up leading to chronic conditions in 10-20 years. The medical and public health communities absolutely must highlight that fact. Many of you probably read my posts and think you're ok because you haven't seen the doctor in over a year. That is a potentially dangerous way of looking at health. The road rage you are experiencing, the long hours you're working, the fast food you're eating, etc. may not be causing you problems in the short term, but it is highly likely that they will lead to chronic conditions in the long term. The problem is, very few take a long term view of things. Look at the profile of the average Medicare beneficiary with the multiple chronic conditions, 10+ meds, 6+ providers. Most of them probably thought they were healthy at one point too.

Posted by: Deron S. | Mar 12, 2009 5:00:10 PM

I think I agree with David. If we really are in the midst of a "bubble" and are aware of being in the "bubble", does it really qualify as a "bubble"? The reason bubbles explode with obvious dire consequences is that everybody is happily and obliviously riding the trend. The sheer fact that we are having this conversation now, combined with the fact that even in the worst scenarios that I can come up with, healthcare will not implode in the next few months, even years, means that there is ample time to come up with a satisfactory solution. I am not entirely convinced that making quick and bold (and possibly reckless) decisions right now is the best course of action and I don't think this should be classified as timidity. Thoughtfulness maybe?

Posted by: Margalit Gur-Arie | Mar 12, 2009 8:38:25 PM

Hello! Very Interesting post! Thank you for such interesting resource! PS: Sorry for my bad english, I'v just started to learn this language ;) See you! Your, Raiul Baztepo

Posted by: RaiulBaztepo | Mar 28, 2009 2:00:23 PM


View the original article here

PHARMA: The ACP does the right thing

In 1937 marijuana was banned by Congress. The only question asked was, "what's the position of the American Medical Association?". It actually was in favor of keeping marijuana legal for medical purposes. But the response given to Congress by whoever was pushing the bill (some diligent drug war historian will tell me who) was that the AMA wanted to ban it. And banned it was. And soon the AMA decided that it didn't approve of medical marijuana--a position it holds to this day

60 years and billions of wasted dollars later, one major physician's group has decided to change its mind. The American College of Physicians is now urging and easing of the ban on medical marijuana. We can only hope that the ridiculous ban on medical marijuana use, despite its therapeutic properties that exceed many FDA approved medications, are closer to being lifted with this type of support.

The medical use of marijuana is handicapped by a major problem. No published study has focused on the smoked form. Most of the recent literature focuses on the specific components, rather than the blend of hundreds of compounds that are present in the native plant.

Further, the smoked form has many carcinogenic chemicals. This issue gets scant coverage. Yes, MJ can give you pain relief, but are you willing to have lung cancer after smoking it for 10 years?

Posted by: Cliff Gevirtz,MD | Feb 19, 2008 6:05:44 AM

"The medical use of marijuana is handicapped by a major problem."

That's is, it can be grown in your own home and doesn't have to be produced by and purchased from big pharma.

I do agree that side effects need to be studied and considerd, but look at every drug ad on TV and you will hear about many side effects that users and docs consider (hopefully) when prescribing. Everything's a trade off.

Posted by: Peter | Feb 19, 2008 6:36:17 AM


View the original article here

Weighing in on the New FDA Commissioner

By MERRILL GOOZNER

Patient advocacy groups, most of them drug industry-funded, have asked President-elect Barack Obama to appoint a Food and Drug Administration commissioner who won't cave in to pressure from lawmakers or the news media, according to the Wall Street Journal.

It is news to me that the news media has much say about decisions at FDA. There are reporters who highlight problems, especially safety problems, in the nation's food and drug supply. And there are reporters who highlight every study suggesting the next miracle cure is just around the corner. Large news organizations like the New York Times have both. For every Gardiner Harris, there is a Gina Kolata. The news media are megaphones. They are not, to use someone else's phrase, the decider.

Vioxx and Avandia didn't come to light because of the press or angry legislators on Capitol Hill. What consumers and patients, legislators and the press learned about the lethal side effects of those drugs was due to diligent researchers like Steve Nissen and Eric Topol and courageous whistleblowers inside the FDA like David Graham. Ditto for most of the other safety scandals that have plagued the agency in this decade.

That said, patient advocates who are worried that the agency under a more safety-conscious commissioner will somehow abandon the search for faster cures should know that their views are well represented inside the transition team. Josh Sharfstein, the Baltimore health commissioner, formerly on Rep. Henry Waxman's staff, who took up cause of making pediatric cold medicines safer, may be leading the effort. But his co-conveners include Greg Simon, who heads a group called . . . da da . . . Faster Cures (not industry-funded, according to Simon). The other team leader is attorney Alta Charo from the University of Wisconsin, whose expertise is primarily in bioethics, not drug safety.

I don't think I'm talking out of school by confirming that I was one of a dozen or so consumer advocates who met with the transition team last week. A memo I prepared on behalf of the Center for Science in the Public Interest will be posted on the transition team's website in short order (as per the president-elect's instructions; he wants the process totally transparent). I raised a number of concerns well beyond the narrow topic of drug safety, including several familiar to regular readers of this blog like rejoining the Helsinki Declaration on protecting human subjects in clinical trials, comparative effectiveness and biogeneric legislation.

Our group didn't get special treatment. As we entered for our one-hour session, a group of patient advocates, including representatives from the National Organization on Rare Diseases (NORD) and several cancer advocacy groups, was leaving. As we departed, a phalanx of lawyers and lobbyists for Advamed, the medical device industry trade association, entered.

When President Clinton took office, he left the sitting FDA commissioner -- David Kessler -- in place. He went on to become a fervent advocate of reining in the tobacco industry, even as he allowed the drug division to drift toward closer collaboration with industry. The current commissioner Andrew von Eschenbach, a faithful servant of the Bush administration with close ties to the cancer research establishment, signaled this week he will resign on inauguration day. I suspect the appointment of a new commissioner will come quickly. There's much work to be done in implementing last year's safety amendments.

But the new commissioner will not have the option of being anti-industry. The drug and biotechnology industries recognize they are at a crossroads. Their blockbusters are coming off patent. The era of personalized medicine based on validated biomarkers is at hand. But as we learn more about these drugs (this week's hearing on EGFr inhibitors like Erbitux and Vectibix and how they don't work on colorectal cancer patients who have the K-RAS mutation is a case in point) means new drugs in the pipeline will be useful to ever smaller segments of the patient population.

Getting the science right, so that the right drugs get to the right patients and only the right patients so that they will be affordable to the health care system as a whole, is the challenge that now confronts agency scientists and whoever becomes the next commissioner. That's not faster cures. That's smarter cures, even as the new commissioner insists that they still meet the agency's statutory hurdles for safety and efficacy.

December 21, 2008 in Pharma | Permalink

Aside from whomever the new FDA commissioner will be, the FDA is really one of the better agencies in government. Dedicated, smart, hard working group of people. They want to protect the American people from harm and, at the same time, get the drugs out to the American people that have the potential to really help them.

The FDA has more often been criticized for being too restrictive than for being too permissive. The trade off is between access to an effective drug versus exposure to unforseen toxic effects.

The truth is that drugs can't be said to have passed the test of time, until they have passed the test of time. I do think that a drug for arthritis (e.g. Vioxx) has to be held to a different standard than a drug for erectile dysfunction (e.g Viagra) and both need to be held to different standards than a drug for pancreatic cancer.

But it will always be a trade off between access versus risk. And the FDA will periodically be criticized for coming down to hard on one side versus the other.

Posted by: Greg Pawelski | Dec 21, 2008 1:28:32 PM


View the original article here

Who should Obama pick for FDA Commissioner?

It seems like everyone in the Pharma Blogosphere and the press is recommending who president-elect Barack Obama should nominate as the new FDA Commissioner to replace Dr. Andrew von Eschenbach.

A few weeks ago, I created the “Who Should Obama Nominate for FDA Commissioner?” online survey to determine who readers of Pharma Marketing News think should be the next FDA Commissioner. I received many interesting comments and decided to open the survey up to as many stakeholders as possible, including consumers, healthcare professionals, former FDA and other government officials, pharmaceutical employees, and others.

I hope readers of The Health Care Blog will also participate (see how below) and I thank Matthew for allowing me to make this post to THCB.

The following is a list of the candidates for FDA Commissioner included in the survey. I chose these based on several news reports and blog posts that suggested them as contenders. Survey respondents can also write in their choice if that person is not on the list.

To date, approximately 400 responses have been collected. The chart shown below gives the overall results from US respondents (approximately 88% of the total).Fdacommiss

Among US health care professional respondents, 55% of whom are somewhat or very supportive of the pharmaceutical industry, a plurality of 36.4% chose Steven Nissen and 20% chose Peter Rost. Woodcock, Wood, and Califf are tied for third place with each having 9% of that group’s vote.

I don’t have nearly enough input from health care professionals to definitively say that Nissen is the front runner. That is why your vote is so important.

Please take a few minutes to tell us who you think President-elect Obama should nominate as the new FDA Commissioner!

Results of this survey will be summarized in the next issue of Pharma Marketing News, which will be published next week.

Your comments are confidential (anonymous) unless you specifically provide your contact information at the end of the survey and allow us to attribute comments to you personally.

Hi John!

I have comment about the list of prospective FDA commissioners. I can't see a single person who is clearly a patient advocate.

We have seen in the last few years the mess you can create at the FDA when its commissioners do not pay attention to the need of the patients. Since the patients are both the ultimate payers and the early victims of mistakes made at the FDA, why not add a strong patient advocate with a background in pharmacology to your list. Someone like Joe Graedon of the People's pharmacy comes to mind, but I'm sure it should be easy to find many people who fit the bill.

Posted by: Gilles Frydman | Dec 11, 2008 7:10:46 AM

It is a sad illustration of how things have gone at the FDA over the past eight years that I think a lot of us would be satisfied with someone -- anyone -- from the evidence-based community.

Posted by: Lex | Dec 11, 2008 9:42:05 AM

Hey John + Matt,

Did you know that Peter Rost was sending out an email blast complaining about this post?

btw, I wrote a piece just today on why people with diabetes should be VERY CONCERNED about who becomes the next FDA Commissioner:

http://www.diabetesmine.com/2008/12/the-fda-in-transition-diabetes-treatment-at-risk.html

Posted by: Amy Tenderich | Dec 11, 2008 12:47:29 PM

It's hard to imagine that the "Consumer, consumer advocate, patient, or other non-industry aligned member of the public" having much of a say in this when they only can muster (so far) 19% of responses. This is shown by the percentage of respondents (75%, including neutral) who are supportive of the pharmaceutical industry in general. I hope Obama's promise of getting industry lobbyists out of absolute control of DC decisions will be honored. That's why I voted for David Kessler.

Posted by: Peter | Dec 12, 2008 5:00:07 AM

None of the above.
The FDA needs a top bottom cleaning of the administrative structure, but most of all the culture of the FDA needs to be more focused on the safety of the patient.
What the FDA needs is for Congress and Lobbyiest to be prohibited from contact with anyone but the Commissioner of the FDA on any Medical Products or issues concerning patient care. Further we need a house cleaning of the CDC.
Ray Ozmon

Posted by: Ray Ozmon | Dec 19, 2008 5:47:56 PM

The new Commissioner should clean up the institutionalized corruption by working with the Congress to:

1. Prohibit FDA regulators from receiving employments, consultant fees and other compensations from the drug or medical device manufacturers for 10 years after leaving FDA.
2. Prohibit sponsors of new drug or medical device application or their representatives (lobbyists) from contacting any employees in the FDA after the application is submitted for consideration. In ancient China, examiners responsible for administering tests to select civil servants would be beheaded if found in contact with any examinees.
Is anyone qualified?
Sin Hang Lee

Posted by: Sin Hang Lee | Dec 23, 2008 6:36:53 PM

Haven't we learned anything about foxes guarding chicken coops? Can an FDA commissioner really serve the patients when special interests are rampant without control? Imagine an FDA chief who first looks at patient needs, and when that is being challenged,remembers that patient needs are what is important.

Posted by: K. Warren | Dec 30, 2008 8:19:56 AM

Rob Califf is the one. He is a patient advocate, a great leader, has a wealth of experience in both clinical and research arenas and has a brilliant mind. Obama has a great opportunity to choose a truly remarkable person in Califf.

Posted by: D. Bowen | Jan 29, 2009 7:11:15 PM


View the original article here